Elan shareholders approve $1 billion share buyback
DUBLIN, April 12
DUBLIN, April 12 (Reuters) - Irish drugmaker Elan won approval from shareholders on Friday to commence a $1 billion share buyback as it seeks to keep them on side and stave off an approach from U.S. investment firm Royalty Pharma
The buyback was priced between $11.25 and $13.00 per share and is part of plans to return cash to investors after the $3.2 billion sale of Elan's interest in multiple sclerosis drug Tysabri. It was backed by 99.2 percent of shareholders at a special meeting.
Royalty said it reserved the right to reduce its indicative approach of $11 per share if the buyback went through but it may also sweeten its proposal by paying more if Tysabri, which Elan still receive royalties for, hits certain sales milestones, two people familiar with the matter told Reuters.
- NOAA employee charged with stealing U.S. dam information
- Special Report: Traffickers use abductions, prison ships to feed Asian slave trade
- Autopsy of slain Missouri teen shows close-range gunshot: report
- Hong Kong protesters march after fruitless talks with government
- Sweden gets two new sightings, as hunt for undersea intruder goes on